Eris Lifesciences Limited (NSEI:ERIS) agreed to acquire 51% stake in Swiss Parenterals Limited for INR 6.4 billion on February 13, 2024. The deal has been approved by board of directors of Eris Lifesciences Limited. Shardul Amarchand Mangaldas & Co led by Nivedita Tiwari, Devesh Pandey, Shilpa Mankar Ahluwalia, Shubhangi Garg, Gouri Puri, Ritwik Bhattacharya, acted as legal advisor to Eris Lifesciences Limited and Swiss Parenterals Limited for the acquisition.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
896 INR | +0.27% | +1.63% | -1.54% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.54% | 1.46B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- ERIS Stock
- News Eris Lifesciences Limited
- Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.